Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Ophthalmology
Financial review
Immunology
ganaplacide - Non-artemisinin plasmodium
falciparum inhibitor
NCT04546633 KALUMI (CKAF156A2203)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Malaria, uncomplicated
Phase 2
292
PCR-corrected and uncorrected Adequate Clinical and Parasitological
Response (ACPR)
KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
Malaria patients 6 months to < 18 years old
Target
Patients
Readout
Milestone(s)
2023
Publication
TBD
2023 priorities
Innovation: Clinical trials
Neuroscience
Global Health
Appendix
Abbreviations
Oncology
Other
Biosimilars
103 Investor Relations | Q4 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation